Market Overview

UPDATE: JP Morgan Cuts PT to $7 on Arena Pharmaceuticals on Belviq Launch Concerns

Share:
Related ARNA
22 Stocks Moving In Friday's Pre-Market Session
Mid-Afternoon Market Update: Crude Oil Up 1%; DragonWave Shares Plunge

JP Morgan maintained Arena Pharmaceuticals (NASDAQ: ARNA) with a Neutral rating and lowered the price target from $8.00 to $7.00.

JP Morgan commented, "We continue to see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia (including slow uptake and a meaningful number of pts not filling their prescription due to a relatively high out-of-pocket cost). In fact, Belviq could well experience a more lackluster launch vs. Qsymia given the drug's higher price and more modest level of efficacy. Maintain Neutral."

Arena Pharmaceuticals closed at $8.34 on Monday.

Latest Ratings for ARNA

DateFirmActionFromTo
Jul 2017CitigroupMaintainsBuy
Jun 2017CitigroupInitiates Coverage OnBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!